press releases
Recent | 2007 | 2006 | 2005 | 2004 | 2003 | 2002
Recent
September 2, 2008 National Institutes of Health Begins Study of CHF Solutions' Aquapheresis Therapy (PDF)
From 2007
February 13, 2007 Landmark UNLOAD Study Published In February 13th edition of the Journal Of American College Of Cardiology (PDF) January 16, 2007 CHF Solutions Promotes David B. Springer To President And Chief Executive Officer, And Ronald M. Nelson To Chief Financial Officer (PDF)
February 13, 2007 Landmark UNLOAD Study Published In February 13th edition of the Journal Of American College Of Cardiology (PDF)
January 16, 2007 CHF Solutions Promotes David B. Springer To President And Chief Executive Officer, And Ronald M. Nelson To Chief Financial Officer (PDF)
September 25, 2006 Five Studies On Aquapheresis™ Therapy Presented At Heart Failure Society Of America Annual Meeting (PDF) June 13, 2006 CHF Solutions, Inc. names David B. Springer President and Chief Operating Officer (PDF) June 13, 2006 CHF Solutions, Inc. named one of “50 Companies to Watch” in the June issue of Medical Device & Diagnostic Industry magazine (PDF) March 12, 2006 Landmark UNLOAD trial results presented - Ultrafiltration's immediate and long-term benefits demonstrated in heart failure patients March 6, 2006 Media Advisory announcing that the UNLOAD Trial Will Be Featured in Late-Breaking Clinical Trial Presentations at 2006 American College of Cardiology Scientific Session (PDF)
September 25, 2006 Five Studies On Aquapheresis™ Therapy Presented At Heart Failure Society Of America Annual Meeting (PDF)
June 13, 2006 CHF Solutions, Inc. names David B. Springer President and Chief Operating Officer (PDF)
June 13, 2006 CHF Solutions, Inc. named one of “50 Companies to Watch” in the June issue of Medical Device & Diagnostic Industry magazine (PDF)
March 12, 2006 Landmark UNLOAD trial results presented - Ultrafiltration's immediate and long-term benefits demonstrated in heart failure patients
March 6, 2006 Media Advisory announcing that the UNLOAD Trial Will Be Featured in Late-Breaking Clinical Trial Presentations at 2006 American College of Cardiology Scientific Session (PDF)
December 6, 2005 Data From Two Published Studies in JACC Show Short- And Long- Term Benefits of Aquapheresis™ Therapy (PDF) April 5, 2005 CHF Solutions Launches Aquadex™ Flexflow™ Fluid Removal System (PDF) March 17, 2005 CHF Solutions Names Michael S. Gebauer Vice President Of Marketing (PDF) January 19, 2005 CHF Solutions Inc. Completes $22.9 Million Financing (PDF)
December 6, 2005 Data From Two Published Studies in JACC Show Short- And Long- Term Benefits of Aquapheresis™ Therapy (PDF)
April 5, 2005 CHF Solutions Launches Aquadex™ Flexflow™ Fluid Removal System (PDF)
March 17, 2005 CHF Solutions Names Michael S. Gebauer Vice President Of Marketing (PDF)
January 19, 2005 CHF Solutions Inc. Completes $22.9 Million Financing (PDF)
From 2004
September 30, 2004 CHF Solutions Clinical Results Presented at the Scientific Meeting of the Heart Failure Society of Amercia (PDF) July 8, 2004 CHF Solutions Initiates Multi-center Clinical Trial of Aquapheresis™ Therapy (PDF) June 22, 2004 CHF Solutions Appoints Paul A. Sobotka Chief Medical Officer (PDF) June 16, 2004 CHF Solutions’ Aquadex System 100 Fluid Removal System Wins Medical Device Excellence Award (PDF) May 17, 2004 CHF Solutions Forms Service Provider Relationship with Fresenius Medical Care (PDF) January 8, 2004 CHF Solutions Receives FDA 510(K) Marketing Clearance for dual lumen Extended Length Catheter (PDF)
September 30, 2004 CHF Solutions Clinical Results Presented at the Scientific Meeting of the Heart Failure Society of Amercia (PDF)
July 8, 2004 CHF Solutions Initiates Multi-center Clinical Trial of Aquapheresis™ Therapy (PDF)
June 22, 2004 CHF Solutions Appoints Paul A. Sobotka Chief Medical Officer (PDF)
June 16, 2004 CHF Solutions’ Aquadex System 100 Fluid Removal System Wins Medical Device Excellence Award (PDF)
May 17, 2004 CHF Solutions Forms Service Provider Relationship with Fresenius Medical Care (PDF)
January 8, 2004 CHF Solutions Receives FDA 510(K) Marketing Clearance for dual lumen Extended Length Catheter (PDF)
From 2003
December 9, 2003 CHF Solutions Receives FDA 510(K) Marketing Clearance for Central Venous Access with Fluid Removal System (PDF) September 21, 2003 Data Shows System 100 Ultrafiltration is Safe, Effective and Reduces Hospital Length of Stay for Heart Failure Patients (PDF)
December 9, 2003 CHF Solutions Receives FDA 510(K) Marketing Clearance for Central Venous Access with Fluid Removal System (PDF)
September 21, 2003 Data Shows System 100 Ultrafiltration is Safe, Effective and Reduces Hospital Length of Stay for Heart Failure Patients (PDF)
From 2002
October 21, 2002 CHF Solutions Appoints Steven F. Brandt Vice President of Marketing (PDF) September 3, 2002 Newark Beth Israel Medical Center is First in Nation to Adopt CHF Solutions System 100 Fluid Removal System (PDF) July 16, 2002 CHF Solutions, Inc., Closes $26.2 Million in Series D Funding (PDF) June 4, 2002 CHF Solutions Receives FDA 510(K) Marketing Clearance for System 100 Fluid Removal System (PDF) March 14, 2002 CHF Solutions Relocates to Minneapolis (PDF) February 4, 2002 CHF Solutions Appoints John L. Erb Chief Executive Officer and Board of Directors Member (PDF)
October 21, 2002 CHF Solutions Appoints Steven F. Brandt Vice President of Marketing (PDF)
September 3, 2002 Newark Beth Israel Medical Center is First in Nation to Adopt CHF Solutions System 100 Fluid Removal System (PDF)
July 16, 2002 CHF Solutions, Inc., Closes $26.2 Million in Series D Funding (PDF)
June 4, 2002 CHF Solutions Receives FDA 510(K) Marketing Clearance for System 100 Fluid Removal System (PDF)
March 14, 2002 CHF Solutions Relocates to Minneapolis (PDF)
February 4, 2002 CHF Solutions Appoints John L. Erb Chief Executive Officer and Board of Directors Member (PDF)
conferences
press contacts
media resources
online conferences
download Aquadex FlexFlow brochure (PDF)
forward this page
print this page
